A promising treatment, retatrutide, is creating considerable buzz within the Australian weight management community. Developed by Eli Lilly , this twin GIP and GLP-1 agonist appears to deliver more substantial results than present therapies. Preliminary medical studies have shown exceptional reductions in overall weight , suggesting the for a new s